Subject archive for "perspective"

Do you know what excites me more than AI? Joining the Domino team as CMO. I know I’m not exactly the only AI enthusiast. Yet there's more to AI than ChatGPT, which may or may not have helped me write this post. Throughout my career, I have worked at the intersection of technology, and data, as I’ve always been fascinated by their transformational impact on organizations. Like all of us, I know we are at an inflection point. The emergence of widely available LLMs highlights the importance of machine learning models and how they redefine how we work, learn, and live. And Domino is already how leading companies make AI happen.

In a never-ending quest to accelerate innovation, healthcare and pharmaceutical companies around the world have been working to modernize their statistical computing environments, streamline clinical trials, and handle the required analytics and reporting.

How do you balance the need for innovation and efficiency in FSI with the need for compliance and good governance? That's a critical question for the financial services and insurance industries to answer, because AI, ML, and the hybrid/multi-cloud are among the most important technology trends of our time.

From early disease detection to intelligent clinical trial designs to personalized medicine, the promise of AI/ML in healthcare and life sciences is great, with “more than 57% of healthcare and life sciences organizations rating AI/ML important or very important, ” according to Ventana Research in their recent white paper Top AI Considerations for Chief Data and Analytics Executives.

Co-written by Andy Lin, Vice President Strategy & Innovation, CTO at Mark III Systems and David Schulman, Head of Partner Marketing at Domino Data Lab.

Will the adoption of new tools and methodologies promote greater innovation and quicker development of new therapies for patients in need? That is a possible result of the FDA’s growing acceptance of the use of the R programming language in the statistical analysis and reporting for clinical trial submissions, which has long been the nearly exclusive province of SAS.